Treatment with ramucirumab, a KDR‐targeting monoclonal antibody, in combination with bevacizumab efficiently reduced tumor growth and angiogenesis in an in vivo xenograft mouse model, suggesting a novel therapeutic strategy for drug‐resistant patients with NSCLC. This evidence concerns the gene KDR and neoplasm.